

Project Title	Curbing atherosclerosis through precision medicine
Principal Investigator	Jean-Claude Tardif
Principal Institution	Montreal Heart Institute
Summary	
<p>Despite the increase in life expectancy, more than 15,000 people die from cardiovascular disease each year in Quebec. This project is led by a team from the Montreal Heart Institute (MHI), allied to major partners in the Quebec pharmaceutical industry and elsewhere, and in collaboration with a network of experts from Quebec universities. Close collaboration will provide in-depth study of DNA and plasma samples provided by clinical trial participants to elucidate the role of certain genes identified by the pioneering pharmacogenomic studies of the MHI, to identify and study the role of new markers derived from "omic" sciences that influence therapies that aim at reducing: 1) "bad cholesterol" or low-density lipoprotein, 2) inflammation of the arteries, 3) adverse effects of type 2 diabetes, and 4) to enhance the function of high density lipoprotein or "good cholesterol". This project will identify the patients who best respond to the therapies of the future and will make tangible the precision medicine whose beneficial effects for patients must reflect on the Quebec health system.</p>	